newsfilter
← Latest News
GlobeNewswire·

CCRN Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Cross Country Healthcare to Knox Lane

  • Wohl & Fruchter LLP has renewed its investigation into the fairness of Cross Country Healthcare's proposed $13.25 per share cash sale to Knox Lane.
  • The original December 2024 agreement for CCRN to be acquired by Aya Healthcare for $18.61 per share was terminated in December 2025 due to regulatory delays from a government shutdown.
  • The new Knox Lane offer announced on May 6, 2026, represents a nearly 29% reduction compared to the prior Aya Healthcare price.
  • Benchmark analysts raised CCRN's target price to $14.00 on March 5, 2026, citing improving outlook & EBITDA margins.
  • Wedbush analysts raised CCRN's target price to $15.00 on March 19, 2026, following increased conviction in revenue stabilization & strategic pivot timing.
  • The investigation follows a review of a definitive proxy filed with the SEC on June 15, 2026, which solicits shareholder approval for a vote scheduled for July 16, 2026.
  • The firm is examining whether the CCRN board acted in shareholders' best interests regarding the sale price & full disclosure of material information.
  • CCRN shareholders may contact Wohl & Fruchter at no charge via phone at 866-833-6245, email at alerts@wohlfruchter.com, or their website for legal consultation.